This CPB has been revised to state that detection of elevated factor VIII and von Willebrand factor levels is considered experimental and investigational for assessment of acute ischemic stroke risk. This CPB has been revised to state that Novoeight Antihemophilic Factor (Recombinant) is considered medically necessary for use in individuals with hemophailia A for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.